

Experimental Medicine

13 March 2019

British Pharmacological Society, London, UK

09:00-09:15	Registration and coffee
09:15-09:30	Welcome and Introduction to the day <i>Dr Daniel Marks, Director, Discovery Medicine, GSK</i>
09:30-10:15	Workshop: Choosing a candidate molecule <i>Dr Mike Kelly, Director of Preclinical Safety, GSK</i>
10:15-11:00	Enabling clinical trials: starting and stopping <i>Dr Mike Kelly, Director of Preclinical Safety, GSK</i>
11:00-11:15	Coffee break
11:15-12:30	Designing a preclinical programme <i>Dr Mike Kelly, Director of Preclinical Safety, GSK</i>
12:30-13:15	Lunch
13:15-13:45	Key statistical principles in early phase clinical development <i>Kirsty Hicks, Director, Clinical Statistics, GSK</i>
13:45-14:30	Futility analysis workshop <i>Kirsty Hicks, Director, Clinical Statistics, GSK</i>
14:30-15:00	What the non-statistician needs to know about Bayesian design <i>Kirsty Hicks, Director, Clinical Statistics, GSK</i>
15:00-15:15	Coffee break
15:15-16:00	Prior elicitation workshop <i>Kirsty Hicks, Director, Clinical Statistics, GSK</i>
16:00-16:50	Quantitative decision making <i>Kirsty Hicks, Director, Clinical Statistics, GSK</i>
16:50-17:00	Closing remarks <i>Dr Daniel Marks, Director, Discovery Medicine, GSK</i>
18:00	Optional workshop dinner

Lunch and refreshments are provided for attendees.